A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
Status:
Not yet recruiting
Trial end date:
2023-05-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through
treatment emergent adverse event (TEAE) and to explore primary and secondary clinical
response of treatment with Augmentin ES in pediatric population presenting with CAP and ABRS
in Brazil.